← Evidence map

ArticleOncogene2026

EGFR amplification and PI3K pathway mutations identify a subset of breast cancers that synergistically respond to EGFR and PI3K inhibition.

David J Wisniewski et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.

4 papers cite it

2026

this papercites it

EGFR amplification and PI3K pathway mutations identify a subset of breast cancers that synergistically respond to EGFR and PI3K inhibition. | Socratic